Advertisement

Gynecology

  • Kathryn S. Brigham
  • Anne Althausen PlanteEmail author
Chapter
Part of the Current Clinical Psychiatry book series (CCPSY)

Abstract

Gynecology care is essential for promoting and maintaining health in all women. Due to multiple obstacles, it is more challenging to deliver consistent and high-quality gynecology care to women with intellectual and emotional disabilities. The cognitive and emotional limitations of each woman’s unique impairment directly impact how and where routine counseling and examinations can best be delivered. Discussion and management of basic genital hygiene, menstrual hygiene and bleeding, premenstrual mood and behavior changes, sexuality, contraception, and fertility are important components of health care for patients with autism spectrum disorder (ASD).

Keywords

Routine gynecology care Genital hygiene Sexuality Vulvar care Menstrual suppression Contraception Sterilization 

References

  1. 1.
    American College of Obstetricians and Gynecologists. Adolescents and long-acting reversible contraception: implants and intrauterine devices. ACOG Committee Opinion No. 539. Obstet Gynecol. 2012;120:983–8.CrossRefGoogle Scholar
  2. 2.
    American College of Obstetricians and Gynecologists. Guidelines for women’s health care: a resource manual. 3rd ed. Washington DC: ACOG; 2007.Google Scholar
  3. 3.
    American College of Obstetricians and Gynecologists. Reproductive health care for adolescents with disabilities. Supplement to Guidelines for Adolescent Health Care. 2nd ed. Washington DC: American College of Obstetricians and Gynecologists; 2012.Google Scholar
  4. 4.
    Bergendal A, Persson I, Odeberg J, et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol. 2014;124:600.CrossRefGoogle Scholar
  5. 5.
    American College of Obstetricians and Gynecologists. Breast cancer screening. ACOG Practice Bulletin No. 122. Obstet Gynecol. 2011;118:372–82.CrossRefGoogle Scholar
  6. 6.
    Blum RW, Kelly A, Ireland M. Health-risk behaviors and protective factors among adolescents with mobility impairments and learning and emotional disabilities. J Adolesc Heath. 2001;28:481–90.CrossRefGoogle Scholar
  7. 7.
    Centers for Disease Control and Prevention. Vaccine safety: human papilloma virus (HPV) vaccine. Available at: http://www.cdc.gov/vaccinesafety/vaccines/HPV/index.html.
  8. 8.
    American College of Obstetricians and Gynecologists. Cervical cytology screening. ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409–20.CrossRefGoogle Scholar
  9. 9.
    Chumlea WC, Schubert CM, Roche AF, Kulin HE, Lee PA, Himes JH, et al. Age at menarche and racial comparisons in US girls. Pediatrics. 2003;111:110–3.CrossRefGoogle Scholar
  10. 10.
    Copen CE, Chandra A, Martinez G. Prevalence and timing of oral sex with the opposite sex partners among female and males ages 15-25years; United States 2007-2010. Natl Health Stat Report. 2012;(56):1–14.Google Scholar
  11. 11.
    Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril. 2009;91:1646.CrossRefGoogle Scholar
  12. 12.
    Darney P, Etonogestrel contraceptive implant. UpToDate. Walters Kluwer Heath 6/24/2016.Google Scholar
  13. 13.
    American College of Obstetricians and Gynecologists. Depot medroxyprogesterone acetate and bone effects. ACOG Committee Opinion No. 415. Obstet Gynecol. 2008;112:727–30.CrossRefGoogle Scholar
  14. 14.
    American College of Obstetricians and Gynecologists. Endometrial ablation ACOG Practice Bulletin No. 81. Obstet Gynecol. 2007;109:1233–48.CrossRefGoogle Scholar
  15. 15.
    Fraser IS, Porte RJ, Kouides PA, Lukes AS. A benefit-risk review of systemic hemostatic agents: part 2: in excessive or heavy menstrual bleeding. Drug Saf. 2008;31:275–82.CrossRefGoogle Scholar
  16. 16.
    Fritz MA, Speroff L. Long-acting methods of contraception. In: Clinical gynecology and infertility. 8th ed. Philadelphia: Walters Kluwer Heath; 2011. p. 1059–93.Google Scholar
  17. 17.
    Harden C, Leppik I. Optimizing therapy for seizures in women who use oral contraceptives. Neurology. 2006;67:S56–8.CrossRefGoogle Scholar
  18. 18.
    American College of Obstetricians and Gynecologists. Human papilloma virus immunization. ACOG Committee Opinion No. 448. Obstet Gynecol. 2010;116:800–3.CrossRefGoogle Scholar
  19. 19.
    Jentick J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, et al. Valproic acid monotherapy in pregnancy and major congenital Malformations. N Engl J Med. 2010;362:2185–93.CrossRefGoogle Scholar
  20. 20.
    Kaunitz AM. Depot medroxyprogesterone acetate for contraception. UpToDate. Walters Kluwer Heath 1/26/2016.Google Scholar
  21. 21.
    Kaunitz AM. Hormonal contraception for suppression of menstruation. UpToDate. May 4, 2016.Google Scholar
  22. 22.
    Kirkham YA, Allen L, Kives S, Caccia N, Spitzer RF, Ornstein MP. Trends in menstrual concerns and suppression in adolescents with developmental disabilities. J Adolesc Health. 2013;53:407–12.CrossRefGoogle Scholar
  23. 23.
    Kluft C, Meijer P, LaGuardia KD, Fisher AC. Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables. Contraception. 2008;77:77.CrossRefGoogle Scholar
  24. 24.
    Knickmeyer RC, Wheelwright S, Hoekstra R, Baron-Cohen S. Age of Menarche in females with autisms spectrum conditions. Dev Med Child Neurol. 2006;48:1007–8.CrossRefGoogle Scholar
  25. 25.
    Krauss GL, Brandt J, Campbell M, Plate C, Summerfield M. Antiepileptic medication and oral contraceptive interactions: a national survey of neurologists and obstetricians. Neurology. 1996;46:1534–9.CrossRefGoogle Scholar
  26. 26.
    Lin K, Barnhart K. The clinical rational for menses-free contraception. J Woman’s health (Larchmt). 2007; 16/1171.Google Scholar
  27. 27.
    Lopez LM, Edelman A, Chen M, et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev. 2013:CD008815.Google Scholar
  28. 28.
    Lopez LM Grimes DA, Schulz KF, Curtis KM. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev. 2011;(7).Google Scholar
  29. 29.
    Lukes AS, Moore KA, Muse KN, Gersten JK, Hecht BR, Edlund M, et al. Tranexamic acid treatment for heavy menstrual bleeding; a randomized controlled trial. Obstet Gynecol. 2010;116:865–75.CrossRefGoogle Scholar
  30. 30.
    Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptives by women with epilepsy. JAMA. 1986;256:238–40.CrossRefGoogle Scholar
  31. 31.
    American College of Obstetricians and Gynecologists. Menstrual manipulation for adolescents with physical and developmental disabilities. ACOG Committee Opinion No. 668. Obstet Gynecol. 2016;128:e20–5.CrossRefGoogle Scholar
  32. 32.
    American College of Obstetricians and Gynecologists. Menstruation in girls and adolescents: using menstrual cycle as a vital sign. ACOG Committee Opinion No. 651. Obstet Gynecol. 2015;126:e143–6.CrossRefGoogle Scholar
  33. 33.
    Milsom I, Korver T. Ovulation incidence with oral contraceptives: a literature review. J Fam Plann Reprod Health Care. 2008;34:237.CrossRefGoogle Scholar
  34. 34.
    American College of Obstetricians and Gynecologists. Options for prevention and management of heavy menstrual bleeding in adolescent patients undergoing cancer treatment. Committee Opinion No. 606. Obstet Gynecol. 2014;124:397.CrossRefGoogle Scholar
  35. 35.
    Pearlman MD, Griffin IL. Benign breast disease. Obstet Gynecol. 2010;116:747–58.CrossRefGoogle Scholar
  36. 36.
    American College of Obstetricians and Gynecologists. Premenstrual syndrome. ACOG Practice Bulletin No. 15. Washington DC; 2000.Google Scholar
  37. 37.
    Quint EH, Elkins TE, Sorg CA, Kope S. The treatment of cyclic behavior changes in women with mental disabilities. J Pediatr Adolesc Gynecol. 1999;12:139–42.CrossRefGoogle Scholar
  38. 38.
    Quint EH. Menstrual and reproductive issues in adolescents with physical and developmental disabilities. Ann N Y Acad Sci. 2008;1135:230–6.CrossRefGoogle Scholar
  39. 39.
    Quint EH. Adolescents with special needs:clinical challenges in reproductive health care. J Pediatr Adolesc Gynecol. 2016;29:2–6.CrossRefGoogle Scholar
  40. 40.
    Reddy DS. Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives. Expert Rev Clin Pharmacol. 210(3):183–92.CrossRefGoogle Scholar
  41. 41.
    Savelli SL, Kerlin BA, Springer MA, Monda KL, Thornton JD, Blanchong CA. Recommendations for screening for thrombophilic tendencies in teenage female prior to contraceptive initiation. J Pediatr Adolesc Gynecol. 2006;19:313–6.CrossRefGoogle Scholar
  42. 42.
    US Prevention Services Task Force. Screening for breast cancer: US Prevention Services Task Force recommendations statement. Ann Intern Med. 2009;151:716–26.CrossRefGoogle Scholar
  43. 43.
    Sobey D, Doe T. Patterns of sexual abuse and assault. Sex Disabil. 1991;9:243–59.CrossRefGoogle Scholar
  44. 44.
    American College of Obstetricians and Gynecologists. Sterilization of women, including those with mental disabilities. ACOG Committee Opinion No. 371. Obstet Gynecol. 2007;110:217–20.CrossRefGoogle Scholar
  45. 45.
    Stewart FH, Harper CC, Ellertson CE, Grimes DA, Sawaya GF, Trussell J. Clinical breast and pelvic examination requirements for hormonal contraception. Current practice vs. evidence. JAMA. 2001;285:2232–9.CrossRefGoogle Scholar
  46. 46.
    Stoegerer-Hecher E, Kirchengast S, Huber JC, Hartmann B. Amenorrhea and BMI as independent determinants of patient satisfaction in LNG-IUD users: cross sectional study in a Central European district. Gynecol Endocrinol. 2012;28:119–24.CrossRefGoogle Scholar
  47. 47.
    American College of Obstetricians and Gynecologists. The initial reproductive health visit. ACOG Committee Opinion No. 598. Obstet Gynecol. 2014;123:1143–7.CrossRefGoogle Scholar
  48. 48.
    U.S. Department of Justice. Office of Victims of Crime. Working with victims of crime with disabilities. Washington DC; 1998.Google Scholar
  49. 49.
    U.S. medical eligibility criteria for contraceptive use, 2016 Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep. 2016;65(3):1–104.Google Scholar
  50. 50.
    American College of Obstetricians and Gynecologists. Use of hormonal contraception in women with coexisting medical conditions. ACOG practice Bulletin # 73. Obstet Gynecol. 2006;107:1453–72.CrossRefGoogle Scholar
  51. 51.
    American College of Obstetricians and Gynecologists. Well-woman visit. ACOG Committee Opinion No. 534. Obstet Gynecol. 2012;120:421–4.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pediatrics, Division of Adolescent and Young Adult Medicine, Massachusetts General HospitalBostonUSA
  2. 2.Department of Obstetrics and Gynecology, Massachusetts General HospitalBostonUSA

Personalised recommendations